The company is focused on the clinical development and commercial exploitation through partnering of its highly innovative antimicrobial drugs and has an open door policy to discussing potential business relationships. These range from partnering and licensing through to investment and non-dilutive funding as well as risk sharing and joint ventures with industry, academia and governments.
Please contact us at email@example.com to start a discussion.
The company has already completed one collaboration with China Medical Systems signed in 2017 who have rights to the XF platform for Greater China and related territories.
- Destiny Pharma to attend the 2020 Bioinfect conference, 12th February 2020, Alderley Park, UK 07/02/2020
- Destiny Pharma to attend Infection Control 2020, 13 February 2020, Birmingham, UK 07/02/2020
- Destiny Pharma to attend 4th AMR Conference: Novel Antimicrobials and AMR Diagnostics, 12 – 13 March 2020, Basel, Switzerland 07/02/2020